Select your country

Africa
Asia
Europe
Latin America
North America
Oceania

MilliporeSigma Announces Collaboration with Solvias for New Pyrogen Detection Kit

MilliporeSigma today announced a collaboration with Solvias, a Swiss contract research and service provider, to offer the PyroMAT™ System, a new MAT kit for pyrogen detection.

29 May 2018 | Burlington, Massachusetts, United States of America
  • Only cell-line-based Monocyte Activation Test (MAT) kit on the market
  • Detects broad spectrum of pyrogens and offers high reproducibility, sensitivity
  • Eliminates the need for live animal testing

MilliporeSigma today announced a collaboration with Solvias, a Swiss contract research and service provider, to offer the PyroMAT™ System, a new MAT kit for pyrogen detection. The kit, which joins other products in MilliporeSigma’s Pyrogen Detection portfolio, was developed collaboratively by the companies.

Because pyrogen contaminations in pharmaceutical products, biotherapeutics and medical devices can induce life-threatening fevers, manufacturers must ensure that pyrogen concentrations do not exceed certain limits. The new PyroMAT™ System, the only cell-line-based MAT kit on the market, detects the full range of pyrogens in pharmaceutical raw materials and products.

“Our new PyroMAT™ System has many advantages over existing methods, which are often limited in the products and range of pyrogens that can be detected,” said Jean-Charles Wirth, Head of Applied Solutions at MilliporeSigma. “This system offers a high-quality, ready-to-use in vitro method that does not require live animal testing and detects the broad spectrum of pyrogens.”

The new kit eliminates the laboratory work required to maintain the cell line, and the cells are qualified in terms of performance and shipment.

“We are pleased that our collaboration with MilliporeSigma to distribute the cell-based test is now coming to fruition,” said Karen Huebscher, CEO, Solvias.  “The new PyroMAT™ System has significant potential through distinct advantages over current methods of testing for pyrogens. It produces results that are both reliable and reproducible, characteristics that are essential for quality assurance.”

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

Downloads

For more information, please contact Karen Tiano

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15.3 billion in 2017. Almost 53,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Related News

Press Releases

MilliporeSigma Makes Major Investment in New Singapore Laboratory

Burlington, Massachusetts, September 18, 2018 – MilliporeSigma today announced the opening of a new 3,800-square-meter laboratory in Singapore.

2018/09/18

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement